Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3267610 | 0.71 | GABRA1 (0.39) | — | |
| SCHEMBL14536231 | 0.70 | NFE2L2 (0.48) | NFE2L2 | |
| SCHEMBL20076508 | 0.66 | ESR1 (0.33) | ESR1ESR2NFE2L2 | |
| SCHEMBL15496489 | 0.66 | ALDH1A1 (0.42) | NFE2L2 | |
| SCHEMBL8062622 | 0.64 | KDM1A (0.39) | NFE2L2 | |
| SCHEMBL10831968 | 0.64 | ALDH1A1 (0.30) | — | |
| SCHEMBL3268739 | 0.64 | ALDH1A1 (0.32) | — | |
| SCHEMBL5084622 | 0.63 | TDP1 (0.44) | ESR1ESR2 | |
| SCHEMBL15180199 | 0.63 | NFE2L2 (0.35) | NFE2L2 | |
| SCHEMBL1051454 | 0.62 | DGAT1 (0.39) | NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | ESR1 4019/4885ESR2 4118/4885NFE2L2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.